Health Care & Life Sciences » Pharmaceuticals | Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc. Cl A | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
22,881.00
76,436.00
149,555.00
273,957.00
298,276.00
346,639
Cost of Goods Sold (COGS) incl. D&A
61,006.00
25,583.00
11,642.00
13,128.00
25,311.00
40,862
Gross Income
38,125.00
50,853.00
137,913.00
260,829.00
272,965.00
305,777
SG&A Expense
213,877.00
215,889.00
222,363.00
302,494.00
380,751.00
407,794
EBIT
252,002.00
165,036.00
102,088.00
42,039.00
108,095.00
102,264
Unusual Expense
-
4,334.00
9,928.00
1,685.00
26,017.00
145,371
Non Operating Income/Expense
-
661.00
-
-
600.00
-
Interest Expense
21,002.00
21,166.00
31,096.00
39,153.00
36,370.00
37,724
Pretax Income
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
Consolidated Net Income
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
Net Income
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
Net Income After Extraordinaries
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
Net Income Available to Common
272,812.00
189,618.00
142,669.00
81,708.00
116,937.00
282,368
EPS (Basic)
2.35
1.39
1.00
0.56
0.78
1.85
Basic Shares Outstanding
115,852.00
136,811.00
142,155.00
144,928.00
148,993.00
152,634
EPS (Diluted)
2.35
1.39
1.00
0.56
0.78
1.85
Diluted Shares Outstanding
115,852.00
136,811.00
142,155.00
144,928.00
148,993.00
152,634
EBITDA
240,273.00
152,705.00
90,458.00
30,779.00
93,478.00
88,041
Other Operating Expense
-
-
17,638.00
374.00
309.00
247
Non-Operating Interest Income
192.00
257.00
443.00
1,169.00
2,111.00
2,991

About Ironwood Pharmaceuticals

View Profile
Address
301 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.ironwoodpharma.com
Updated 07/08/2019
Ironwood Pharmaceuticals, Inc. operates as commercial biotechnology company, which discovers, develops and commercializes differentiated medicines that improve patient's lives. Its products include linaclotide, a guanylate cyclase type-C agonist being developed for the treatment of patients with irritable bowel syndrome with constipation and chronic constipation; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout. The company was founded by Peter M.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.